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Identity 
Other names: PHLPP; KIAA0606; MGC161555; 
PLEKHE1; SCOP 




The gene for PHLPP1 is located at 18q21.33. It 
encompasses two different splice variants: 
PHLPP1alpha and PHLPP1beta. PHLPP1alpha spans 
154 kb and includes 16 exons. The PHLPP1beta gene is 
identical to the PHLPP1alpha gene except that it has a 
much (~1.5 kb) longer exon 1 and a slightly shorter 
exon 2. Including the new exon 1, the PHLPP1beta 
gene is 265 kb in length. PHLPP1 is one of two 
separate genes in the PHLPP gene family; the second 
gene, PHLPP2, is located at 16q22.3. 
Transcription 
The PHLPP1alpha and PHLPP1beta transcripts are 
identical except for exon 1 and the beginning of exon 2. 
The PHLPP1alpha transcript is 4617 bp; the 
PHLPP1beta transcript is 6155 bp. 
Protein 
Description 
The PHLPP1alpha and PHLPP1beta proteins both 
contain a pleckstrin homology (PH) domain, a series of 
leucine-rich repeats (LRR), a PP2C phosphatase 
domain, and a C-terminal PDZ (post synaptic density 
protein [PSD95], Drosophila disc large tumor 
suppressor [DlgA], and zonula occludens-1 protein [zo-
1]) binding motif. In addition, PHLPP1beta has a 
putative Ras association (RA) domain near its N-
terminus. PHLPP1alpha is composed of 1205 amino 
acids and has a molecular weight of approximately 133 
kDa, while PHLPP1beta has 1717 amino acids and a 
molecular weight of approximately 185 kDa. (The 
related isoform PHLPP2 has a domain structure similar 
to that of PHLPP1beta). 
Expression 
PHLPP1 is expressed in most human cancer cell lines
and all mouse tissues examined so far. PHLPP1beta 
appears to be more abundant than PHLPP1alpha. Rat 
PHLPP1beta (termed SCOP for Suprachiasmatic 
nucleus circadian oscillatory protein) is also exprssed 
in the suprachiasmatic nucleus, where its mRNA 
expression oscillates in a circadian fashion. 
 
Genomic organization of the PHLPP1alpha and PHLPP1beta transcripts. Exons are represented by blue (PHLPP1alpha) or red 
(PHLPP1beta) boxes, and position along chromosome 18 is indicated by the scale bar at the top. 
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PHLPP1alpha and PHLPP1beta protein structure. 
 
Localisation 
PHLPP1 appears to be localized throughout the cell. 
Function 
PHLPP1 is a phosphatase that specifically 
dephosphorylates the hydrophobic motif (HM) of Akt 
and conventional/novel PKC isoforms. HM 
phosphorylation is important for the function of both 
kinases. For Akt, phosphorylation at serine 473, the 
HM site, allows full activation of the kinase and 
subsequent phosphorylation of its downstream 
substrates. For PKC, phosphorylation of the HM 
(serine 660 in PKCbetaII) increases protein stability; 
once the HM is dephosphorylated, two other important 
regulatory sites on the kinase (the activation loop and 
the turn motif) are rendered more sensitive to 
dephosphorylation by other phosphatases. The 
dephosphorylated PKC is then shunted to the detergent-
insoluble fraction of the cell, where it is degraded. 
PHLPP1 therefore functions to decrease the activity of 
both Akt and PKC, albeit by different mechanisms. 
While PHLPP1 and its family member PHLPP2 have 
similar functions, their specificity for Akt isoforms 
differs. PHLPP1 preferentially binds and 
dephosphorylates Akt2 and Akt3, resulting in 
decreased phosphorylation of a set of Akt targets that
includes GSK-3beta, TSC2, and FoxO, as well as and 
GSK3a. PHLPP2, on the other hand, binds and 
dephosphorylates Akt1 and Akt3, resulting in 
downregulation of an overlapping yet distinct set of 
downstream targets: GSK-3beta, TSC2, and FoxO, as 
well as TSC2 and p27. 
Interestingly, PHLPP1's regulation of its protein 
substrates appears to be regulated by its protein-protein 
interaction domains. PHLPP1 lacking a C-terminal 
PDZ ligand is unable to dephosphorylate Akt, whereas 
deletion of PHLPP1's PH domain decreases its ability 
to dephosphorylate PKC. 
Since PHLPP1 downregulates the pro-survival kinase 
Akt, it is not surprising that this phosphatase plays roles 
in apoptosis and suppression of cellular proliferation. 
siRNA-mediated reduction of PHLPP1 causes 
increased apoptosis in a number of cell lines, whereas 
overexpression of PHLPP1 decreases proliferation in 
LN229, a glioblastoma cell line, and suppresses its 
ability to form tumors in nude mice. 
PHLPP1 also regulates the phosphorylation and activity 
of ERK; it has been suggested to interact directly with 
the nucleotide-free form of K-Ras and thus suppress the 
Ras/Raf/MEK/ERK pathway. This pathway is 
important for the regulation of learning and memory, 
and overexpression of rat PHLPP1beta in the 
hippocampus of transgenic mice abolishes memory for 
novel objects. In addition, training for hippocampus-
based learning prompts calpain protease-mediated 
degradation of PHLPP1. Together, these results suggest 
that proper regulation of PHLPP1 in certain neurons is 
crucial for memory formation. 
Homology 
PHLPP is a highly conserved phosphatase; its earliest 
orthologue is the yeast protein CYR1. In addition t a 
PP2C phosphatase domain, a leucine-rich repeat, and a 
Ras association domain, CYR1 contains an adenylate 
cyclase domain near its C terminus. Though 
invertebrates have only one PHLPP gene, most 
vertebrates have genes for both PHLPP1 and PHLPP2. 
Mutations 
Somatic 
One glioblastoma multiforme sample was found to 
have a mutation in the catalytic domain of PHLPP1 
(M738T in the PHLPP1a transcript). This tumor sample 
presented with mutations in several other known tumor 




PHLPP1 overexpression in human LN229 cells limits 
their ability to form tumors in a xenograft model. 
Various human glioblastoma cell lines respond to 
PHLPP1 knockdown with increased Akt 
phosphorylation. In addition, mRNA expression of both 
PHLPP1 and PHLPP2 are decreased by around 30% in 
patient glioblastoma samples (relative to normal brin). 
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Colorectal cancer 
Cytogenetics 
18q21.33, the chromosomal locus containing the gene  
for PHLPP1 as well as the putative tumor suppressors 
BCL2 and Maspin, commonly undergoes loss of 
heterozygosity in colon cancers. 
Oncogenesis 
Overexpression of PHLPP1 or PHLPP2 in the human 
colon cancer cell lines HCT-116 and HT29 causes 
decreased expression of PKC and decreased 
phosphorylation of Akt. Cells overexpressing PHLPP 
exhibit decreased proliferation and were less able to 
induce tumors in nude mice. Conversely, DLD1 cells, 
which express high levels of PHLPP, respond to 
PHLPP1 or PHLPP2 knockdown with increased Akt 
phosphorylation, PKC stability, and proliferation. 
Leukemia 
Disease 
Chronic lymphocytic leukemia, chronic myelogenous 
leukemia 
Oncogenesis 
PHLPP1 mRNA expression is frequently reduced to 
undetectable levels in patients with chronic 
lymphocytic leukemia (CLL). About 50% of CLL 
patients have loss of chromosomal region 13q14, and 
about 50% of these show drastically reduced PHLPP1 
expression. In chronic myelogenous leukemia (CML), 
PHLPP mRNA levels may also be decreased, albeit by 
a different mechanism. Bcr-Abl, the fusion protein 
responsible for CML, downregulates PHLPP1 and 
PHLPP2 mRNA levels; decreasing PHLPP levels 
interferes with the efficacy of Bcr-Abl inihibitors, 
including Gleevec, in CML cell lines. 
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